Cardiff Names Interim Medical Chief Ahead of Phase III

Company Cardiff Oncology Event Type Leadership change (interim CMO) Modality Oral PLK1 inhibitor Asset Onvansertib Target Polo-like kinase 1 (PLK1) Disease Area RAS-mutated metastatic colorectal cancer Summary Cardiff Oncology named Leila Alland interim chief medical officer on 27 October after Roger Sidhu stepped down. The…